Hims & Hers Health Inc. (NYSE:HIMS) shares are plummeting Monday ahead of its third-quarter earnings report, which is scheduled for release after the market close.
- Hims & Hers Health stock is taking a hit today. What’s pressuring HIMS stock?
Hims & Hers Stock Falls Ahead of Earnings
Last quarter gave investors a mixed picture, with sales that beat forecasts and earnings that missed them. Hims & Hers shares are sliding before the new report, which traders may be positioning for the results. Wall Street projects a 6-cent profit per share and $892.89 million in revenue.
That revenue target is roughly 19% higher than the $753.21 million Hims & Hers reported in the second quarter. A year earlier, revenue was $544.83 million, and the second quarter total also cleared the $699.89 million consensus.
Profit went the other way, with a 37-cent loss per share against a 3-cent loss expected, so analysts now expect a turn to positive earnings. Subscribers reached almost 2.9 million in the second quarter, 19% more than a year earlier.
Management also raised its 2026 sales forecast in that report, to $3.1 billion up to $3.3 billion, and the $3.2 billion midpoint sat about 9% above the $2.93 billion analysts had estimated.
What a Beat or Miss Would Mean for Hims & Hers
Earnings above 6 cents a share would mean Hims & Hers made more than analysts expected, while anything below would mean smaller profit or a loss. Revenue above $892.89 million would show sales running ahead of forecasts, as in the second quarter, and a lower figure would show sales falling behind.
Investors will also watch the full-year outlook. A higher range than the $3.1 billion to $3.3 billion set last quarter would extend that raise.
Since the second quarter delivered a revenue beat and earnings miss, investors may check whether both lines move in the same direction this time.
HIMS Shares Are Sliding
HIMS Price Action: Hims & Hers shares were down 10.31% at $23.32 at the time of publication on Monday, according to Benzinga Pro.
Read Also: Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain?
Image: PJ McDonnell/Shutterstock